Page 24 - Strategies for non-invasive managementof high-grade cervical intraepithelial neoplasia - prognostic biomarkers and immunotherapy Margot Maria Koeneman
P. 24
Chapter 1
17. Stanley MA. Epithelial cell responses to infection with human papillomavirus. Clin Microbiol Rev. 2012;25(2):215-22.
18. Patel S, Chiplunkar S. Host immune responses to cervical cancer. Curr Opin Obstet Gynecol. 2009;21(1):54-9.
19. Arbyn M, Xu L, Simoens C, Martin-Hirsch PP. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev. 2018;5:CD009069.
20. Mesher D, Panwar K, Thomas SL, Edmundson C, Choi YH, Beddows S, et al. The Impact of the National HPV Vaccination Program in England Using the Bivalent HPV Vaccine: Surveillance of Type-Specific HPV in Young Females, 2010-2016. J Infect Dis. 2018.
21. Newman PA, Logie CH, Lacombe-Duncan A, Baiden P, Tepjan S, Rubincam C, et al. Parents’ uptake of human papillomavirus vaccines for their children: a systematic review and meta- analysis of observational studies. BMJ Open. 2018;8(4):e019206.
22. Donken R, Tami A, Knol MJ, Lubbers K, van der Sande MAB, Nijman HW, et al. Changes in (risk) behavior and HPV knowledge among Dutch girls eligible for HPV vaccination: an observational cohort study. BMC Public Health. 2018;18(1):837.
23. Bruni L, Diaz M, Barrionuevo-Rosas L, Herrero R, Bray F, Bosch FX, et al. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. Lancet Glob Health. 2016;4(7):e453-63.
24. Vaccinatiegraad Rijksvaccinatieprogramma Nederland. Jaarverslag 2016. RIVM Rapport 2016-0064. Accessible at: https://www.rivm.nl/dsresource?objectid=89ece336-f681-43c2- abc0-7213e87f6b6b&type=org&disposition=inline. Accessed Juli 9, 2018.
25. Human papillomavirus vaccines. WHO position paper. Wkly Epidemiol Rec. 2009 Apr 10;84(15):118-31.
26. Capra G, Giovannelli L, Matranga D, Bellavia C, Guarneri MF, Fasciana T, et al. Potential impact of a nonavalent HPV vaccine on HPV related low-and high-grade cervical intraepithelial lesions: A referral hospital-based study in Sicily. Hum Vaccin Immunother. 2017;13(8):1839- 43.
27. Bogani G, Taverna F, Lombardo C, Signorelli M, Chiappa V, Casarin J, et al. Potential impact of introducing a nonavalent HPV vaccination. Int J Gynaecol Obstet. 2018.
28. Lam JU, Rebolj M, Dugue PA, Bonde J, von Euler-Chelpin M, Lynge E. Condom use in prevention of Human Papillomavirus infections and cervical neoplasia: systematic review of longitudinal studies. J Med Screen. 2014;21(1):38-50.
29. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 2010;11(3):249-57.
30. Rijkaart DC, Berkhof J, Rozendaal L, van Kemenade FJ, Bulkmans NW, Heideman DA, et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol. 2012;13(1):78-88.
31. Wright TC, Stoler MH, Behrens CM, Sharma A, Zhang G, Wright TL. Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gynecol Oncol. 2015;136(2):189-97.
22
